|
Shaping the Future Traditional treatment pathways are reported to be ineffective in up to 70% of patients. In light of this, Sarah Trenfield and Dr Alvaro Goyanes at FabRx urge companies to embrace tailored therapies and, namely, 3D printing. Sarah Trenfield and Dr Alvaro Goyanes at FabRx (April 2019)
|